Arena Pharmaceuticals, Inc. et al v. Aurobindo Pharma Limited et al
Eisai Inc., 356 Royalty Inc. and Arena Pharmaceuticals, Inc. |
Aurobindo Pharma USA, Inc. and Aurobindo Pharma Limited |
1:2019cv00811 |
May 1, 2019 |
US District Court for the District of Delaware |
Richard G Andrews |
Patent - Abbreviated New Drug Application(ANDA) |
35 U.S.C. § 271 |
None |
Docket Report
This docket was last retrieved on December 9, 2019. A more recent docket listing may be available from PACER.
Document Text |
---|
|
|
Filing 30 PROPOSED Stipulated Protective Order, by 356 Royalty Inc., Arena Pharmaceuticals, Inc., Eisai Inc.. (Raucci, Anthony) Modified on 12/5/2019 (nms). |
|
|
|
Filing 27 NOTICE OF SERVICE of (1) Aurobindo's response to Plaintiffs' First Set of Interrogatories (Nos. 1-9); (2) Aurobindo's response to Plaintiffs' First Set of Requests for Production (Nos. 1-55); and (3) Aurobindo's response to Plaintiffs' First Set of Requests for Admission (Nos. 1-18) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
|
Filing 26 STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to November 20, 2019 - filed by 356 Royalty Inc., Arena Pharmaceuticals, Inc., Eisai Inc.. (Blumenfeld, Jack) |
|
|
Filing 24 NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Regarding Custodians and Non-Custodial Data Sources; and (2) Plaintiffs' Initial Disclosures Identifying Aurobindo's Accused Product and Plaintiffs' Asserted Patents filed by 356 Royalty Inc., Arena Pharmaceuticals, Inc., Eisai Inc..(Raucci, Anthony) |
Filing 23 STIPULATION TO EXTEND TIME for the parties to submit a proposed protective order to November 6, 2019 - filed by 356 Royalty Inc., Arena Pharmaceuticals, Inc., Eisai Inc.. (Raucci, Anthony) Modified on 10/31/2019 (nms). |
Filing 22 NOTICE OF SERVICE of Aurobindo's Paragraph 3 Disclosures filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
|
Filing 20 NOTICE OF SERVICE of (1) Plaintiffs' Rule 26(a)(1) Initial Disclosures; (2) Plaintiffs' First Set of Requests for Production of Documents and Things from Aurobindo (Nos. 1-55); (3) Plaintiffs' First Set of Interrogatories (Nos. 1-9); and (4) Plaintiffs' First Set of Requests for Admission (Nos. 1-18) filed by 356 Royalty Inc., Arena Pharmaceuticals, Inc., Eisai Inc..(Blumenfeld, Jack) |
Filing 19 NOTICE OF SERVICE of Initial disclosures pursuant to FRCP 26(a) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
|
|
|
CORRECTING ENTRY: The order filed at D.I. 18 has been removed as it was filed in error. (nms) |
CASE REFERRED to Chief Magistrate Judge Mary Pat Thynge for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at # https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf (cak) |
Filing 15 PROPOSED Scheduling Order, by Eisai Inc.. (Attachments: #1 Letter)(Raucci, Anthony) Modified on 9/27/2019 (nms). |
Filing 14 MOTION for Pro Hac Vice Appearance of Attorney David A. Chen - filed by 356 Royalty Inc., Arena Pharmaceuticals, Inc., Eisai Inc.. (Raucci, Anthony) |
|
Pro Hac Vice Attorney Young J. Park for 356 Royalty Inc., for Arena Pharmaceuticals, Inc., for Eisai Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
Pro Hac Vice Attorney Bruce M. Wexler for 356 Royalty Inc., for Arena Pharmaceuticals, Inc., for Eisai Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
Pro Hac Vice Attorney Melanie R. Rupert for 356 Royalty Inc., for Arena Pharmaceuticals, Inc., for Eisai Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
Filing 13 MOTION for Pro Hac Vice Appearance of Attorney Bruce M. Wexler, Young J. Park and Melanie R. Rupert - filed by 356 Royalty Inc., Arena Pharmaceuticals, Inc., Eisai Inc.. (Raucci, Anthony) |
|
|
Filing 11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma U.S.A., Inc. for Aurobindo Pharma Limited filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
Filing 10 ANSWER to #1 Complaint, by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
|
Filing 9 STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to September 3, 2019 - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) Modified on 8/20/2019 (nms). |
Filing 8 AFFIDAVIT of Service for Complaint and related documents served on Aurobindo Pharma Limited on July 31, 2019, filed by 356 Royalty Inc., Arena Pharmaceuticals, Inc., Eisai Inc.. (Blumenfeld, Jack) |
Filing 7 SUMMONS Returned Executed by Arena Pharmaceuticals, Inc., 356 Royalty Inc., Eisai Inc.. Aurobindo Pharma USA, Inc. served on 7/30/2019, answer due 8/20/2019. (Blumenfeld, Jack) |
Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Eisai Co., Ltd. for Eisai Inc. - filed by Eisai Inc. (amf) |
Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Arena Pharmaceuticals, Inc. for 356 Royalty Inc. - filed by 356 Royalty Inc. and Arena Pharmaceuticals, Inc. (amf) |
Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,953,787 B2 ;7,514,422 B2; 7,977,329 B2; 8,207,158 B2; 8,273,734 B1; and 9,770,455 B2. (amf) |
Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 3/20/2019. Date of Expiration of Patent: See attached form.Thirty Month Stay Deadline: 9/20/2021. (amf) |
Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (amf) |
Filing 1 COMPLAINT FOR PATENT INFRINGEMENT - filed against Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. - Magistrate Consent Notice to Pltf. (Filing fee $ 400, receipt number 0311-2632513) - filed by Arena Pharmaceuticals, Inc., 356 Royalty Inc., and Eisai Inc. (Attachments: #1 Exhibits A-F, #2 Civil Cover Sheet)(amf) |
Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. on 5/1/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (amf) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.